Related Experiment Video
Updated: Aug 2, 2026
06:47
Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products
Published on: December 5, 2020
Comparative molecular field analysis of anticoccidial triazines
1Central Research Division, Pfizer Inc., Groton, Connecticut 06340.
Journal of Medicinal Chemistry
|July 10, 1992
Summary
This study used Comparative Molecular Field Analysis (CoMFA) to correlate anticoccidial potency of triazines with physical properties. The model accurately predicted drug efficacy using steric, electrostatic, lipophilicity, and acidity data.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Parasitology
Background:
- Coccidiosis is a significant parasitic disease in animals.
- Developing effective anticoccidial agents is crucial for animal health.
- Quantitative Structure-Activity Relationship (QSAR) studies aid in drug design.
Purpose of the Study:
- To establish a Quantitative Structure-Activity Relationship (QSAR) model for anticoccidial triazines.
- To identify key physicochemical properties influencing anticoccidial potency.
- To predict the efficacy of novel triazine derivatives.
Main Methods:
- Comparative Molecular Field Analysis (CoMFA) was employed.
- Biological data from a whole animal infectious disease model were utilized.
- Steric, electrostatic, lipophilicity, and acidity data were incorporated into the CoMFA model.
Main Results:
- An excellent correlation was achieved between triazine anticoccidial potencies and their physical properties.
- CoMFA provided a quantitative description of steric and electrostatic field effects.
- The developed model successfully predicted the potencies of novel triazine compounds.
Conclusions:
- Physicochemical properties, including lipophilicity and acidity, are critical determinants of anticoccidial activity in triazines.
- CoMFA is a valuable tool for understanding structure-activity relationships in drug discovery.
- The predictive model can guide the design of more potent anticoccidial agents.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...